PATENT CLAIM ANALYSIS

Application Number: 15984018
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "183000"]

Abstract:
Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.

Claim (Index 16):
The method of  claim 14 , wherein the second active agent is dexamethasone.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 93.0
- Lexical Diversity: 1.4902
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12621502', '12221651', '14781898', '12070451', '13889473']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7847310696991121
- 35 USC 102 Novelty (BERT): 0.5565247383072026
- Combined Prediction Score: 0.7619104365599212
- Mean Citation Score: 372.158252
- Max Citation Score: 440.8632
- Similarity Product: 326.2035603618622

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test